Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Measurement of health-related quality of life in patients with amyotrophic lateral sclerosis in clinical trials of new therapies.

Damiano AM, Patrick DL, Guzman GI, Gawel MJ, Gelinas DF, Natter HM, Ingalls KK.

Med Care. 1999 Jan;37(1):15-26.

PMID:
10413388
2.

Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.

Ackerman SJ, Sullivan EM, Beusterien KM, Natter HM, Gelinas DF, Patrick DL.

Pharmacoeconomics. 1999 Feb;15(2):179-95.

PMID:
10351191
3.

Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.

Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Murphy MF, Natter HM, Norris FH, Rudnicki SA.

Neurology. 1997 Dec;49(6):1621-30.

PMID:
9409357
4.

Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group.

Lange DJ, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Lai EC, Murphy MF, Natter HM, Norris FH, Rudnicki S.

Neurology. 1996 Oct;47(4 Suppl 2):S93-4; discussion S94-5. No abstract available.

PMID:
8858058
5.

Post-anesthesia uncal herniation secondary to a previously unsuspected temporal glioma.

Vender JR, Black P, Natter HM, Katsetos CD.

J Forensic Sci. 1995 Sep;40(5):900-2.

PMID:
7595336
6.

Incidence of cavum septum pellucidum in adults: a sign of boxer's encephalopathy.

Bogdanoff B, Natter HM.

Neurology. 1989 Jul;39(7):991-2.

PMID:
2739929
7.

Malignant hyperthermia susceptibility in X-linked muscle dystrophies.

Heiman-Patterson TD, Natter HM, Rosenberg HR, Fletcher JE, Tahmoush AJ.

Pediatr Neurol. 1986 Nov-Dec;2(6):356-8.

PMID:
3508709

Supplemental Content

Loading ...
Support Center